StockNews.AI
GH
StockNews.AI
201 days

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

1. Guardant Health will report Q4 and full year 2024 results on February 20, 2025. 2. The conference call will provide insights into company performance and future outlook. 3. Guardant focuses on precision oncology, improving outcomes through advanced testing. 4. Webcast will be available for replay, expanding accessibility to financial results. 5. Company's performance could impact investor confidence and stock valuation.

Earnings
-5.93%Current Return
VS
-0.53%S&P 500
$49.9401/30 04:28 PM EDTEvent Start
$46.9801/31 10:51 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report is anticipated but not likely to significantly shift GH's stock price. Past similar announcements have had mixed results on stock movement.

How important is it?

While earnings announcements are impactful, GH's prior results have shown volatility. Current market conditions may further influenc the impact.

Why Short Term?

The immediate impact will relate to the earnings release. Long-term effects depend on ongoing business performance post-announcement.

Related Companies

GH
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Related News